Evidence map›Paper›PMID 39981203›Full record

ArticleFrontiers in rehabilitation sciences2025

Case Report: Combination of focal vibration therapy and botulinum toxin injections to treat equinus gait in a child with unilateral spastic cerebral palsy.

Christophe Boulay, Jacques-Olivier Coq, Morgan Sangeux, Guillaume Authier, Alexis Ulian, Maud Pradines, Marjolaine Baude, Béatrice Desnous, Jean-Luc Jouve, Bernard Parratte and 3 more

Abstract readCase Reports
In one paragraph

Article in Frontiers in rehabilitation sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Christophe BoulayGait Laboratory, Pediatric Orthopaedic Surgery Department, Timone Children's Hospital, Marseille, France.
Jacques-Olivier CoqInstitut des Sciences du Mouvement (ISM), Equipe DynamiCC, UMR 7287 CNRS/Aix Marseille Université, Marseille, France.
Morgan SangeuxGait Laboratory, Pediatric Orthopaedic Surgery Department, Timone Children's Hospital, Marseille, France.
Guillaume AuthierGait Laboratory, Pediatric Orthopaedic Surgery Department, Timone Children's Hospital, Marseille, France.
Alexis UlianGait Laboratory, Pediatric Orthopaedic Surgery Department, Timone Children's Hospital, Marseille, France.
Maud PradinesAP-HP, Service de Rééducation Neurolocomotrice, Unité de Neurorééducation, Hôpitaux Universitaires Henri Mondor, Créteil, France.
Marjolaine BaudeAP-HP, Service de Rééducation Neurolocomotrice, Unité de Neurorééducation, Hôpitaux Universitaires Henri Mondor, Créteil, France.
Béatrice DesnousPediatric Neurology Department, Timone Children's Hospital, Marseille, France.
Jean-Luc JouveGait Laboratory, Pediatric Orthopaedic Surgery Department, Timone Children's Hospital, Marseille, France.
Bernard ParratteGait Laboratory, Pediatric Orthopaedic Surgery Department, Timone Children's Hospital, Marseille, France.
Emilie PeltierGait Laboratory, Pediatric Orthopaedic Surgery Department, Timone Children's Hospital, Marseille, France.
Sébastien PesentiGait Laboratory, Pediatric Orthopaedic Surgery Department, Timone Children's Hospital, Marseille, France.
Jean-Michel GraciesAP-HP, Service de Rééducation Neurolocomotrice, Unité de Neurorééducation, Hôpitaux Universitaires Henri Mondor, Créteil, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Focal vibration therapy (FVT) is increasingly used in the treatment of spastic paresis. In adults, it has been shown to reduce spasticity and to increase torque production from the vibrated muscles by restoring reciprocal inhibition of antagonists, thereby improving overall gait. In children with spastic cerebral palsy (CP), FVT has also been suggested to reduce spasticity, increase torque production and improve gait function, but evidence is limited. Methods: We report the case of a child with unilateral spastic CP (USCP) and equinus gait (GFMCS II level) with (i) ankle dorsiflexor paresis, (ii) ankle plantar flexor overactivity, especially in gastrosoleus complex and peroneus longus, (iii) spastic myopathy, affecting gastrosoleus complex in particular, and (iv) calf pain seemingly related to muscle overactivity. The child was treated with a two-month program of alternating dorsiflexor and plantar flexor focal vibration therapy (FVT) and botulinum neurotoxin A (BoNT-A) injections into plantar flexors, alongside conventional physiotherapy. Results and discussion: Clinical evaluations during the two-month program showed (i) improved walking speed (ii) decreased ankle dorsiflexor paresis and ankle plantar flexor overactivity, especially spastic co-contraction and spasticity, (iii) improved passive extensibility in plantar flexors, and (iv) reduced pain. This is the first report of the combination of FVT and BoNT-A injections having promising effects on equinus gait in USCP.

Indexed as

botulinum neurotoxin Achildren with cerebral palsyequinusfive-step assessmentfocal vibration therapy

Identifiers

PMID39981203
PMCPMC11839612

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.